Učitavanje...

AZD9291 in epidermal growth factor receptor inhibitor—resistant non-small-cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in advanced EGFR mutant non-small cell lung cancer have an objective response rate (ORR) of approximately 60–70% and a median progression free-survival (PFS) of approximately 10-13 months. Studies of tumor biopsies performed a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Transl Lung Cancer Res
Glavni autor: Stinchcombe, Thomas E.
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2016
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4758967/
https://ncbi.nlm.nih.gov/pubmed/26958499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.19
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!